文献速递炎症性肠病

系统综述与网络Meta分析:中重度溃疡性结肠炎内科干预对健康相关生活质量的影响

Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
PubMed 文献 · Aliment Pharmacol Ther · 2018-10-30

该系统综述与网络Meta分析检索至2017年10月的随机对照试验,比较英夫利西单抗、阿达木单抗、戈利木单抗、维得利珠单抗或托法替布对中重度溃疡性结肠炎患者健康相关生活质量的影响。诱导治疗中所有药物较安慰剂显著改善生活质量评分,但仅英夫利西单抗和维得利珠单抗的IBDQ改善具有临床意义;维持治疗证据稀疏且不确定。

要点

  • 诱导治疗中所有药物较安慰剂显著改善通用和疾病特异性生活质量评分,证据置信度低至极低。
  • 仅英夫利西单抗(MD 18.58;95%CI 13.19-23.97)和维得利珠单抗(MD 18.00;95%CI 11.08-24.92)的IBDQ改善具有临床意义。
  • 维持治疗中维得利珠单抗、托法替布和阿达木单抗维持生活质量改善,证据置信度极低。

核心结论

  • 英夫利西单抗、阿达木单抗、戈利木单抗、维得利珠单抗或托法替布的诱导治疗较安慰剂改善生活质量。
  • 维持治疗证据稀疏且不确定。
  • 头对头比较可增强对药物间健康相关生活质量差异结论的信心。

研究设计与样本

  • 检索Medline、Embase、CENTRAL和灰色文献来源至2017年10月。
  • 纳入比较英夫利西单抗、阿达木单抗、戈利木单抗、维得利珠单抗或托法替布相互之间或与安慰剂的随机对照试验。
  • 共纳入14项随机对照试验,采用IBDQ(14项试验)、SF-36(7项试验)或EQ-5D(3项试验)评估健康相关生活质量。
  • 进行随机效应成对和网络Meta分析,使用CINeMA框架评估证据置信度。

主要发现

  • 诱导治疗(13项试验)中,低至极低置信度证据提示所有药物较安慰剂显著改善通用和疾病特异性健康相关生活质量评分。
  • 仅英夫利西单抗(MD 18.58;95% CI 13.19-23.97)和维得利珠单抗(MD 18.00;95% CI 11.08-24.92)的IBDQ评分改善具有临床意义。
  • 各干预之间的差异不精确。
  • 维持治疗(4项试验)中,极低置信度证据提示维得利珠单抗、托法替布和阿达木单抗维持健康相关生活质量改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 诱导治疗证据置信度为低至极低。
  • 维持治疗证据置信度为极低。
  • 各干预之间的差异不精确。
  • 维持治疗证据稀疏且不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient-reported outcomes are important in the assessment of efficacy of intervention for ulcerative colitis (UC). AIM: To compare the impact of interventions for moderate-to-severe UC on health-related quality of life (HRQL). METHODS: We searched Medline, Embase, CENTRAL and grey literature sources through October 2017. We included randomised controlled trials (RCTs) that compared infliximab, adalimumab, golimumab, vedolizumab or tofacitinib to each other or placebo. Outcomes included the change in quality of life scores and the proportion of patients with improvement in quality of life. We performed random-effect pairwise and network meta-analysis. We assessed confidence in estimates using the CINeMA (Confidence in Network Meta-Analysis) framework. RESULTS: Fourteen RCTs assessed HRQL using the Inflammatory Bowel Disease Questionnaire (IBDQ) (14 trials), the Short Form questionnaire-36 (SF-36) (seven trials) or the European Quality of Life-5 Dimensions questionnaire (EQ-5D) (three trials). At induction (13 trials), low to very low confidence evidence suggested that all agents significantly improved both generic and disease-specific HRQL scores compared to placebo. However, only infliximab (MD 18.58; 95% CI 13.19-23.97) and vedolizumab (MD 18.00; 95% CI 11.08-24.92) showed clinically meaningful improvement in IBDQ score. Differences among individual interventions were imprecise. For maintenance (four trials), very low confidence evidence suggested that vedolizumab, tofacitinib and adalimumab maintained improvement in HRQL. CONCLUSIONS: Induction treatment with infliximab, adalimumab, golimumab, vedolizumab or tofacitinib improves quality of life compared to placebo. Evidence on maintenance therapy is sparse and uncertain. Head-to-head comparisons could enhance confidence in conclusions about differences between drugs in terms of HRQL.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Paschos P, Katsoula A, Salanti G, et al. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther. 2018. PMID: 30378141. doi:10.1111/apt.15005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。